Pfizer Inc. (PFE) is seeking expanded FDA approval of BOSULIF to include first-line treatment of patients with chronic phase Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML).This supplemental new drug application for BOSULIF in the first-line setting is under priority review by the FDA, with a decision expected in December. BOSULIF is already approved by the FDA for the treatment of adult patients with Ph+ CML who are resistant to or intolerant to prior therapy.PFE closed Tuesday’s (Nov.28) trading at $35.85, up 1.01%.